Multiple serum markers in patients with endometrial cancer

Pierluigi Benedetti Panici, Giovanni Scambia, Gabriela Baiocchi, Lidia Perrone, Stefano Greggi, Francesco Battaglia, Salvatore Mancuso

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

Serum levels of carcinoembryonic antigen (CEA), CA 125 and CA 15-3 were measured in 47 patients with endometrial cancer and 20 with endometrial hyperplasia. Before treatment elevated serum levels of CEA, CA 125 and CA 153 were found in 14, 43 and 32% of cancer patients, respectively. In the 20 patients with endometrial hyperplasia, CEA and CA 15-3 values were normal, while elevated CA-125 titers were detected in 1 case. There was an increasing incidence of abnormal levels of all markers in relation to a higher tumor stage (stage I: 36%; II: 66%; III: 100%). The percentage of positive marker values increased in case of deep myometrial infiltration (> M1) and/or poorer tumor differentiation (> G1). However, only percent increase in CA 153 positivity was significantly higher in more infiltrating (> M1, 7 vs. 65%, p <0.01) and less differentiated (> G1, 0 vs. 47%, p = 0.01) tumors. These findings suggest that CA 153 is in some way associated with the prognostic factors of the disease. All patients except 2 with no evidence of disease after surgery had normal serum marker values. Moreover, CA 125 and CA 153 levels reflected the clinical course of the disease during chemotherapy and seemed to be useful for monitoring response to treatment.

Original languageEnglish
Pages (from-to)208-212
Number of pages5
JournalGynecologic and Obstetric Investigation
Volume27
Issue number4
DOIs
Publication statusPublished - 1989

Fingerprint

Endometrial Neoplasms
Carcinoembryonic Antigen
Biomarkers
Endometrial Hyperplasia
Neoplasms
Mucin-1
Serum
Reference Values
Drug Therapy
Incidence
Therapeutics

Keywords

  • Endometrial cancer
  • Tumor markers

ASJC Scopus subject areas

  • Obstetrics and Gynaecology
  • Reproductive Medicine

Cite this

Panici, P. B., Scambia, G., Baiocchi, G., Perrone, L., Greggi, S., Battaglia, F., & Mancuso, S. (1989). Multiple serum markers in patients with endometrial cancer. Gynecologic and Obstetric Investigation, 27(4), 208-212. https://doi.org/10.1159/000293658

Multiple serum markers in patients with endometrial cancer. / Panici, Pierluigi Benedetti; Scambia, Giovanni; Baiocchi, Gabriela; Perrone, Lidia; Greggi, Stefano; Battaglia, Francesco; Mancuso, Salvatore.

In: Gynecologic and Obstetric Investigation, Vol. 27, No. 4, 1989, p. 208-212.

Research output: Contribution to journalArticle

Panici, PB, Scambia, G, Baiocchi, G, Perrone, L, Greggi, S, Battaglia, F & Mancuso, S 1989, 'Multiple serum markers in patients with endometrial cancer', Gynecologic and Obstetric Investigation, vol. 27, no. 4, pp. 208-212. https://doi.org/10.1159/000293658
Panici, Pierluigi Benedetti ; Scambia, Giovanni ; Baiocchi, Gabriela ; Perrone, Lidia ; Greggi, Stefano ; Battaglia, Francesco ; Mancuso, Salvatore. / Multiple serum markers in patients with endometrial cancer. In: Gynecologic and Obstetric Investigation. 1989 ; Vol. 27, No. 4. pp. 208-212.
@article{d8b0989b1f1a44e5a491a9f7d3068681,
title = "Multiple serum markers in patients with endometrial cancer",
abstract = "Serum levels of carcinoembryonic antigen (CEA), CA 125 and CA 15-3 were measured in 47 patients with endometrial cancer and 20 with endometrial hyperplasia. Before treatment elevated serum levels of CEA, CA 125 and CA 153 were found in 14, 43 and 32{\%} of cancer patients, respectively. In the 20 patients with endometrial hyperplasia, CEA and CA 15-3 values were normal, while elevated CA-125 titers were detected in 1 case. There was an increasing incidence of abnormal levels of all markers in relation to a higher tumor stage (stage I: 36{\%}; II: 66{\%}; III: 100{\%}). The percentage of positive marker values increased in case of deep myometrial infiltration (> M1) and/or poorer tumor differentiation (> G1). However, only percent increase in CA 153 positivity was significantly higher in more infiltrating (> M1, 7 vs. 65{\%}, p <0.01) and less differentiated (> G1, 0 vs. 47{\%}, p = 0.01) tumors. These findings suggest that CA 153 is in some way associated with the prognostic factors of the disease. All patients except 2 with no evidence of disease after surgery had normal serum marker values. Moreover, CA 125 and CA 153 levels reflected the clinical course of the disease during chemotherapy and seemed to be useful for monitoring response to treatment.",
keywords = "Endometrial cancer, Tumor markers",
author = "Panici, {Pierluigi Benedetti} and Giovanni Scambia and Gabriela Baiocchi and Lidia Perrone and Stefano Greggi and Francesco Battaglia and Salvatore Mancuso",
year = "1989",
doi = "10.1159/000293658",
language = "English",
volume = "27",
pages = "208--212",
journal = "Gynecologic and Obstetric Investigation",
issn = "0378-7346",
publisher = "S. Karger AG",
number = "4",

}

TY - JOUR

T1 - Multiple serum markers in patients with endometrial cancer

AU - Panici, Pierluigi Benedetti

AU - Scambia, Giovanni

AU - Baiocchi, Gabriela

AU - Perrone, Lidia

AU - Greggi, Stefano

AU - Battaglia, Francesco

AU - Mancuso, Salvatore

PY - 1989

Y1 - 1989

N2 - Serum levels of carcinoembryonic antigen (CEA), CA 125 and CA 15-3 were measured in 47 patients with endometrial cancer and 20 with endometrial hyperplasia. Before treatment elevated serum levels of CEA, CA 125 and CA 153 were found in 14, 43 and 32% of cancer patients, respectively. In the 20 patients with endometrial hyperplasia, CEA and CA 15-3 values were normal, while elevated CA-125 titers were detected in 1 case. There was an increasing incidence of abnormal levels of all markers in relation to a higher tumor stage (stage I: 36%; II: 66%; III: 100%). The percentage of positive marker values increased in case of deep myometrial infiltration (> M1) and/or poorer tumor differentiation (> G1). However, only percent increase in CA 153 positivity was significantly higher in more infiltrating (> M1, 7 vs. 65%, p <0.01) and less differentiated (> G1, 0 vs. 47%, p = 0.01) tumors. These findings suggest that CA 153 is in some way associated with the prognostic factors of the disease. All patients except 2 with no evidence of disease after surgery had normal serum marker values. Moreover, CA 125 and CA 153 levels reflected the clinical course of the disease during chemotherapy and seemed to be useful for monitoring response to treatment.

AB - Serum levels of carcinoembryonic antigen (CEA), CA 125 and CA 15-3 were measured in 47 patients with endometrial cancer and 20 with endometrial hyperplasia. Before treatment elevated serum levels of CEA, CA 125 and CA 153 were found in 14, 43 and 32% of cancer patients, respectively. In the 20 patients with endometrial hyperplasia, CEA and CA 15-3 values were normal, while elevated CA-125 titers were detected in 1 case. There was an increasing incidence of abnormal levels of all markers in relation to a higher tumor stage (stage I: 36%; II: 66%; III: 100%). The percentage of positive marker values increased in case of deep myometrial infiltration (> M1) and/or poorer tumor differentiation (> G1). However, only percent increase in CA 153 positivity was significantly higher in more infiltrating (> M1, 7 vs. 65%, p <0.01) and less differentiated (> G1, 0 vs. 47%, p = 0.01) tumors. These findings suggest that CA 153 is in some way associated with the prognostic factors of the disease. All patients except 2 with no evidence of disease after surgery had normal serum marker values. Moreover, CA 125 and CA 153 levels reflected the clinical course of the disease during chemotherapy and seemed to be useful for monitoring response to treatment.

KW - Endometrial cancer

KW - Tumor markers

UR - http://www.scopus.com/inward/record.url?scp=0024605662&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024605662&partnerID=8YFLogxK

U2 - 10.1159/000293658

DO - 10.1159/000293658

M3 - Article

VL - 27

SP - 208

EP - 212

JO - Gynecologic and Obstetric Investigation

JF - Gynecologic and Obstetric Investigation

SN - 0378-7346

IS - 4

ER -